Type1 Diabetes Mellitus Clinical Trial
Official title:
Evaluating Glucose Control in Patients With Type 1 Diabetes Under Free-living Conditions With the Insulet Automated Glucose Control System: IDE3
NCT number | NCT03216460 |
Other study ID # | IDE3 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 4, 2019 |
Est. completion date | May 28, 2019 |
Verified date | July 2019 |
Source | Insulet Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting.
Status | Completed |
Enrollment | 120 |
Est. completion date | May 28, 2019 |
Est. primary completion date | May 28, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Age at time of consent 2.0-85 years 2. Individuals aged =6.0 must be diagnosed with type 1 diabetes for at least one year. Preschool children aged 2.0-5.9 years must be diagnosed with type 1 diabetes for at least 6 months. Diagnosis is based on investigator's clinical judgment. 3. A1C <10% at screening 4. Currently using U-100 rapid-acting insulin analogs with insulin pump or receiving multiple daily injections suitable for conversion to pump therapy for at least 3 months prior to study start 5. Willing to use the study CGM device for the duration of the study 6. Willing to use the Omnipod® Insulin Management System during the study 7. Willing to perform all fingerstick BG testing with the study-approved glucose meter at the frequency specified in the study protocol or per investigator discretion 8. Willing to participate in setpoint and meal challenges 9. Willing to use carbohydrate counting for determination of meal boluses 10. Willing to participate in moderate intensity exercise for at least 30 minutes per day 11. Willing to refrain from use of acetaminophen and supplemental vitamin C (>2000 mg/daily) for the entire duration of participation in the study 12. Willing and able to sign the Informed Consent Form (ICF) and/or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from pediatric and adolescent subjects per State requirements. Exclusion Criteria: 1. One or more episodes of severe hypoglycemia requiring emergency room (ER) visit or hospitalization within the past 6 months 2. One or more episodes of diabetic ketoacidosis requiring ER visit or hospitalization within the past 6 months 3. Planning to start a non-insulin anti-diabetic medication during the study. If on non-insulin medication, dose must be stable in the previous 30 days. 4. Using a basal insulin with a usual duration of insulin action > 36 hours 5. Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD or implant) 6. Dermatological conditions at the proposed sensor/pump wear sites that in the investigator's opinion could preclude ability to wear the Pod and/or the Dexcom sensor 7. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12 months. Abnormal electrocardiogram consistent with increased risk of arrhythmia, ischemia, or prolonged QT interval (> 440 ms). Electrocardiogram is only required for subjects >50 years old or with diabetes duration >20 years. 8. Stroke 9. Known history of seizure disorder 10. Known history of adrenal insufficiency 11. Current renal or hepatic disease 12. Untreated or unstable hypothyroidism or celiac disease (per investigator's judgment) 13. Currently undergoing cancer treatment 14. Currently undergoing systemic treatment with steroids or immunosuppressive medication 15. Known history of any chronic infections that would interfere with participation in the study or place study personnel at undue risk due to blood-borne contaminants 16. Current illness that would interfere with participation in the study 17. Untreated or inadequately treated mental illness 18. Current alcohol abuse per investigator's judgment 19. Electrically-powered implants that may be susceptible to RF interference 20. Currently participating in another clinical study using an investigational drug or device 21. Recent (within the preceding 30 days) participation in a clinical study using an investigational drug 22. Unable to follow the clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment. |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Denver | Denver | Colorado |
United States | Yale University School of Medicine | New Haven | Connecticut |
United States | Stanford University | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Insulet Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of time in hypoglycemic range (defined as < 70 mg/dL) | 96 hours | ||
Primary | Percentage of time in hyperglycemic range (defined as = 250 mg/dL) | 96 hours | ||
Secondary | Mean Glucose | 96 hours | ||
Secondary | Percentage of time < 50 mg/dL | 96 hours | ||
Secondary | Percentage of time < 54 mg/dL | 96 hours | ||
Secondary | Percentage of time < 60 mg/dL | 96 hours | ||
Secondary | Percentage of time > 180 mg/dL | 96 hours | ||
Secondary | Percentage of time = 300 mg/dL | 96 hours | ||
Secondary | Percentage of time between 70-180 mg/dL | 96 hours | ||
Secondary | Percentage of time between 70-140 mg/dL | 96 hours | ||
Secondary | Standard deviation | Using CGM measurements, the Standard deviations will be reported for the entire hybrid closed-loop phase overall, as well as separately during the day (0700 - 2259h) and during the night (2300 - 0659h). | 96 hours | |
Secondary | Coefficient of variation | Using CGM measurements, the Coefficient of variation will be reported for the entire hybrid closed-loop phase overall, as well as separately during the day (0700 - 2259h) and during the night (2300 - 0659h). | 96 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Withdrawn |
NCT03396484 -
Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT03117998 -
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
|
Phase 2 | |
Recruiting |
NCT03369821 -
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
|
||
Completed |
NCT03202732 -
DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes
|
N/A | |
Completed |
NCT03704818 -
Dapagliflozin Effects on Hypoglycemia
|
Phase 1 | |
Recruiting |
NCT03864991 -
Lifestyle Changes and Glycemic Control in T1D
|
N/A | |
Completed |
NCT03725657 -
Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
|
||
Completed |
NCT02985866 -
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
|
N/A | |
Completed |
NCT03003806 -
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study
|
N/A | |
Withdrawn |
NCT04147637 -
FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
|
N/A | |
Completed |
NCT03970889 -
Real-time Reminders To Decrease Late or Missed Meal Boluses
|
N/A | |
Recruiting |
NCT04589325 -
Ixekizumab Diabetes Intervention Trial (I-DIT)
|
Phase 2 | |
Completed |
NCT03367390 -
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
|
Phase 1 | |
Completed |
NCT03738852 -
Mechanisms for Restoration of Hypoglycemia Awareness
|
Early Phase 1 | |
Completed |
NCT03406585 -
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03859856 -
Ovarian Reserve in Diabetes Mellitus
|
||
Withdrawn |
NCT04102202 -
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Terminated |
NCT03353792 -
Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients
|
N/A | |
Recruiting |
NCT03811470 -
China Diabetes Registry by Metabolic Management Center
|